Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk myelodysplastic syndrome.

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

A key differentiator for Rytelo is that it can be used to treat patients with or without ring sideroblasts – blood cells with a characteristic circle of iron deposits around their nucleus.

Moreover, while Reblozyl was only cleared for use as second-line therapy in MDS patients with ring sideroblasts – blood cells with a characteristic circle of iron deposits around their nucleus ...

This trial included patients with MDS/MPN-unclassifiable, atypical CML, MDS/MPN with ring sideroblasts and thrombocytosis, and chronic neutrophilic leukemia. These diseases fall under the category of ...

Erythroblasts possess unique characteristics as they undergo differentiation from hematopoietic stem cells. During terminal erythropoiesis, these cells incorporate large amounts of iron in order to ...

In their original work, Xicoy et al. describe the hybrid entity of chronic myelomonocytic leukemia with ring sideroblasts and SF3B1 mutation, which is strikingly similar to the entity of MDS with low ...

Dr. Daniel Leonard (Medicine): A 65-year-old woman was transferred to this hospital for evaluation of pancytopenia and back pain. The patient had been in her usual state of health until 3 weeks ...

The Martin Jädersten group is investigating biological and clinical aspects of acute myeloid leukemia (AML) and runs academic trials exploring novel treatment strategies. The team leader Martin ...